Jerry Durso has more than 30 years of experience building and leading commercial and business operations across the life sciences industry in the United States and abroad. He is a commercial-stage public company executive with a long track record of success at the intersection of strategy and operations, driving growth across diverse business models and therapeutic areas including rare disease, specialty, hospital, and mass market products.
Mr. Durso most recently served as Chief Executive Officer and a member of the Board of Directors of Intercept Pharmaceuticals, a company focused on liver diseases, where he built a successful rare disease franchise, transformed the corporate strategy, and ultimately led the company through its successful acquisition by Alfasigma. Prior to becoming CEO, he served as Intercept’s Chief Operating Officer from 2017 to 2021.
Before Intercept, Mr. Durso spent over two decades at Sanofi, a global pharmaceutical company, where he oversaw multiple blockbuster franchises while holding senior leadership positions including Chief Commercial Officer of Sanofi’s Global Diabetes Division and Chief Commercial Officer of its U.S. Pharmaceuticals business.
Mr. Durso joined the Board of Directors of Altimmune in February 2025 and was named Chairman of the Board in August 2025. He assumed the role of President and Chief Executive Officer in January 2026.
Mr. Durso earned his BBA in Marketing from the University of Notre Dame.
